4DMedical Ltd (ASX:4DX) Stock Price, Trades & News

4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	5.54
Equity-to-Asset	-0.2
Debt-to-Equity	-0.36
Debt-to-EBITDA	-0.06
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	49.34	Distress Grey Safe
Beneish M-Score	-2.62	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	75.4
	3-Year EBITDA Growth Rate	11.8
	3-Year EPS without NRI Growth Rate	-5.9
	3-Year FCF Growth Rate	-6
	3-Year Book Growth Rate	-21.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	45.32
	Future 3-5Y Total Revenue Growth Rate Estimate	116.62

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	39.6
	9-Day RSI	49.52
	14-Day RSI	51.08
	3-1 Month Momentum %	-47.13
	6-1 Month Momentum %	-13.32
	12-1 Month Momentum %	1228

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.58
	Quick Ratio	6.48
	Cash Ratio	5.87
	Days Inventory	739.02
	Days Sales Outstanding	77.11
	Days Payable	2719.46

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-30.6
	Shareholder Yield %	-2.6

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	91.7
	Operating Margin %	-890.77
	Net Margin %	-2903.13
	EBITDA Margin %	-2808.14
	FCF Margin %	-588.2
	OCF Margin %	-580.25
	ROE %	-517.4
	ROA %	-147.2
	ROIC %	-55.67
	3-Year ROIIC %	-14.98
	ROC (Joel Greenblatt) %	-2248.11
	ROCE %	-173.6
	Moat Score	4
	Tariff Resilience Score	5

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	346.66
	EV-to-EBIT	-14.72
	EV-to-EBITDA	-15.23
	EV-to-Revenue	427.48
	EV-to-Forward-Revenue	3.02
	EV-to-FCF	-79.44
	Price-to-GF-Value	2.89
	Earnings Yield (Greenblatt) %	-6.81
	FCF Yield %	-1.35

GF Value™: A$1.44

ASX:4DX

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 4DX. Try a 7-Day Free Trial to check it out.

4DMedical Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

4DMedical Ltd Stock Events

Financials Calendars

	Event	Date	Price (A$)
No Event Data

Press Release

	Subject	Date
	4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union	2026-03-30
	4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging	2026-01-26
	4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology	2025-09-04
	4DMedical and Imbio Merge to Create Comprehensive Cardiothoracic Image Analysis Portfolio	2023-12-11
	Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio	2023-12-11
	4DMedical receives U.S. FDA clearance for CT LVAS Lung Function Scanning Software	2023-11-22

10/Page

Articles on 4DMedical Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.